Bruker Co. (NASDAQ:BRKR) Receives $70.50 Average Price Target from Brokerages

Bruker Co. (NASDAQ:BRKR) has been given an average rating of “Moderate Buy” by the eleven research firms that are presently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $70.50.

Several research firms have commented on BRKR. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a report on Monday, February 24th. UBS Group began coverage on Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target for the company. Stifel Nicolaus dropped their target price on Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a report on Friday, February 14th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price for the company in a report on Thursday, December 5th. Finally, Barclays dropped their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a report on Monday, February 10th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. True Wealth Design LLC boosted its position in Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after buying an additional 510 shares during the last quarter. Eagle Bay Advisors LLC boosted its position in Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after buying an additional 674 shares during the last quarter. UMB Bank n.a. boosted its position in Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after buying an additional 248 shares during the last quarter. GAMMA Investing LLC boosted its position in Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after buying an additional 412 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its position in shares of Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock worth $75,000 after purchasing an additional 196 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $46.94 on Thursday. The business has a 50 day moving average price of $53.38 and a 200 day moving average price of $58.22. Bruker has a twelve month low of $44.11 and a twelve month high of $94.86. The company has a market cap of $7.12 billion, a price-to-earnings ratio of 61.76, a PEG ratio of 2.16 and a beta of 1.18. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Research analysts predict that Bruker will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.43%. Bruker’s dividend payout ratio is 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.